Biomedical Engineering Reference
In-Depth Information
333. Hooijberg JH, Broxterman HJ, Heijn M, Fles DL, Lankelma J, Pinedo HM. 1997. Modu-
lation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS
Lett 413: 344-348.
334. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SPC. 2001. Modulation of multidrug
resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with
dietary flavonoids. Mol Pharmacol 59: 1171-1180.
335. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K,
Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M. 1998. Enhancement of
chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal
anti-inflammatory drugs (NSAIDs). Eur J Cancer 34: 1250-1259.
336. Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, Cotter FE. 2002. In vitro and in vivo
downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma
therapy. Int J Cancer 98: 128-133.
337. Kurz EU, Cole SP, Deeley RG. 2001. Identification of DNA-protein interactions in the 5
flanking and 5
untranslated regions of the human multidrug resistance protein (MRP1)
gene: evaluation of a putative antioxidant response element/AP-1 binding site. Biochem
Biophys Res Commun 285: 981-990.
338. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy RT, Ishikawa T, Kuo MT. 1998.
Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine
synthetase
genes
is
regulated
by
oxidative
stress.
J
Biol
Chem
273:
31075-
31085.
339. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI,
Schrenk DC. 2002. Influence of redox-active compounds and PXR-activators on human
MRP1 and MRP2 gene expression. Toxicology 171: 137-146.
340. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH.1997.
Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes
LRP and MRP. J Natl Cancer Inst 89: 807-813.
341. Ikegami Y, Tatebe S, Lin-Lee YC, Xie QW, Ishikawa T, Kuo MT. 2000. Induction of
MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta
is mediated by nitric oxide-related signalings in human colorectal cancer cells. J Cell
Physiol 185: 293-301.
342. Wijnholds J, Evers R, van Leusden MR, Mol CAAM, Zaman GJR, Mayer U, Beijnen JH,
van der Valk M, Krimpenfort P, Borst P. 1997. Increased sensitivity to anticancer drugs
and decreased inflammatory response in mice lacking the multidrug resistance-associated
protein. Nat Med 11: 1275-1279.
343. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper
RJ, Borst P. 1998. Multidrug resistance protein 1 protects the oropharyngeal mucosal
layer and the testicular tubules against drug-induced damage. J Exp Med 188: 797-
808.
344. Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M,
Schinkel AH, Scheper RJ, Breimer DD, Borst P. 2000. Multidrug resistance protein 1
protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid
barrier. J Clin Invest 105: 279-285.
345. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. 2001. The pharmacological
phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer
Res 61: 1469-1476.
Search WWH ::
Custom Search